hotspot -WSS

hotspot

author：explore 2025-10-02 20:48:48 - browse：667

A new asthma treatment that could be administered just once every six months has succeeded in two Phase 3 trials, developer GlaxoSmithKline announced Tuesday.

The drug, depemokimab, is designed to treat asthma by targeting a protein called interleukin-5, or IL-5. The protein is linked to the type of inflammation found in most severe asthma cases, according to the pharma company.

Depemokimab hit its primary endpoints in the trials, reducing asthma attacks over a year’s time frame. The company didn’t disclose exact details from the SWIFT-1 and SWIFT-2 trials.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How to save PrEP access — and even expand it
Next article： FDA approves first blood sugar monitor without finger pricks

WSS

Trump lawyer welcomes Pence testifying in Jan. 6 trial, won't say if Trump will too

Prince Harry and Meghan to work on film adaptation of 'Meet Me at the Lake' novel

Men with early prostate cancer can safely opt out of treatment

Why workplace violence is so common in health care

Teen said 'homophobic slurs' before O'Shae Sibley killing: Criminal complaint

Thousands in Haiti march to demand safety from violent gangs as killings and kidnappings soar

entertainment

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

In age of alternative facts, a scholarly course on calling out crap

Boeing's 1st astronaut flight bumped into next year, more repairs needed

Bright Health sells Medicare Advantage business to Molina

Moderna hits safety problems in bold bid to reinvent medicine

Activists slam private health insurers over coverage restrictions

'The Earth is screaming at us': Gov. Inslee calls for climate action amid record heat

Anesthesiologist group: stop taking Ozempic before surgery

Doctors have an ethical obligation to be advocates

Duchenne breakthrough therapy leaves behind pioneering families

Thousands protest mob assault of women who were paraded naked in remote Indian border state

hotspot

How a key Senate committee is planning to regulate PBMs

Statins reduce cardiovascular risk in people living with HIV

Elon Musk says he may need surgery before proposed 'cage match' with Mark Zuckerberg

Why workplace violence is so common in health care

The response to Covid

Malaysia cuts short music fest after British band slams anti

knowledge

hotspot

hotspot

entertainment